Novartis Investigative Site

Sestroretsk 197706

0 studies enrolling now · 13 studies all time

What they study most

Acute Myocardial Infarction, Asthma, Atherosclerosis, Cardiovascular Disease and Lipoprotein(a), Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia, Cytokine Storm (Covid-19), Heart Failure With Preserved Ejection Fraction, Muscle Wasting (Atrophy) After Hip Fracture Surgery, Psoriatic Arthritis, Relapsing Multiple Sclerosis

Studies at this site

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS — Running, not enrolling
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI — Completed
Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia — Completed
Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm — Completed
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis — Completed
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. — Completed
Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment — Stopped early
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction — Completed
Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery — Completed
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis — Completed
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis — Completed